Moffitt at AACR

Can AI Predict Who Responds to Immunotherapy?

A deep learning platform uses routine pathology slides to better predict treatment response in lung cancer patients

New KRAS-Targeted Drugs Show Early Signals in Advanced Lung Cancer

Investigational therapies show tumor shrinkage in patients after standard treatments stop working

When Tumor Structure Shapes Immune Response

Study finds collagen remodeling can trap and suppress cancer-fighting T cells, helping explain why some patients don’t respond to immunotherapy

Turning the Immune System Back On: A New Approach to Treating Breast Cancer

Blocking a specific enzyme may unlock the immune system’s potential to attack tumors

Why Do Cancer Immunotherapy Side Effects Differ Among Patients?

Moffitt researchers find genetics may help predict severe colon inflammation in melanoma care

New Oral Targeted Therapy Shows Benefit in Hard to Treat Cancers

Early phase trial results show signs of tumor response and disease control in patients with advanced melanoma, colon, ovarian, cervical and thymic cancers

New Research Offers Hope for KRAS-Driven Lung Cancer

Study explores how blocking cancer’s survival pathway may improve responses in KRAS-mutant lung cancer

Combined Biopsy Strategy Identifies More Targets, Improves Survival in Advanced Tumors

Patients whose tissue and liquid biopsies revealed the same genomic alterations saw better survival rates with targeted therapy compared to standard treatments

Cancer-Related Fatigue and Depression Linked to Reduced Recreational Activity in Survivors

Study shows female cancer survivors are more likely to experience lasting fatigue and depression that impact quality of life

New AI Tool Offers Hope for Early Detection of Cancer Cachexia

The Moffitt model combines imaging and clinical data to improve diagnosis and treatment

New Oral Drug Shows Promise for Patients with HER2-Mutated Lung Cancer

Beamion LUNG-1 trial results highlight zongertinib’s strong tumor control and durable responses

Can Immunotherapy Spare Certain Patients From Surgery?

Dostarlimab offers organ preservation and better quality of life for patients with mismatch repair-deficient tumors